Gabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial

Barbara J. Mason, Ph.D.
Professor, Committee on the Neurobiology of Addictive Disorders
Director, Laboratory of Clinical Psychopharmacology

THE SCRIPPS RESEARCH INSTITUTE®
## Faculty Disclosure

<table>
<thead>
<tr>
<th>Company</th>
<th>Nature of Affiliation</th>
<th>Unlabeled Product Usage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer</td>
<td>Provided study drug (Neurontin) and placebo</td>
<td>Gabapentin</td>
</tr>
</tbody>
</table>
Financial Disclosure

Investigators have no relevant financial interests to disclose.

Study drug for the clinical trial component was provided by Pfizer Pharmaceuticals, Inc.

Funding for the lab study and clinical trial were provided by NIAAA grants number AA012602 and AA014028, respectively.
Educational Objectives:

1. Identify symptoms of an alcohol use disorder
2. Understand the role of medications in treating alcohol dependence
3. Identify symptoms of relapse risk after alcohol withdrawal
4. Evaluate the research data assessing the risks and benefits of gabapentin in patients with alcohol dependence
What is a Standard Drink?

12 fl oz of regular beer = 5 fl oz of table wine = 1.5 fl oz shot of 80-proof spirits ("hard liquor"—whiskey, gin, rum, vodka, tequila, etc.)

- About 5% alcohol for beer
- About 12% alcohol for wine
- About 40% alcohol for spirits

The percent of “pure” alcohol, expressed here as alcohol by volume (alc/vol), varies by beverage.
Definitions

• Moderate “Low Risk” Drinking
  o Women: ≤ 3 drinks on any single day AND ≤ 7 drinks per week
  o Men: ≤ 4 drinks on any single day AND ≤ 14 drinks per week

• Heavy “At Risk” Drinking
  o Women: ≥ 4 drinks on any single day OR > 7 drinks per week
  o Men: ≥ 5 drinks on any single day OR > 14 drinks per week

• Binge Drinking: BAC reaches 0.08g/dL within 2 hours
  o Women: ≈ 4 drinks
  o Men: ≈ 5 drinks
DSM IV: Alcohol Dependence (≥3 of the following):

DSM V: Alcohol Use Disorder (≥2; moderate severity ≥4 of the following):

A problematic pattern of alcohol use within a 12-month period:

1. Often drinking more than was intended
2. Unsuccessful attempts to cut-down or control alcohol use
3. A great deal of time spent in alcohol-related activities
4. Activities given up or reduced because of drinking
5. Continue drinking despite alcohol-related physical or psychological problems
6. Tolerance
7. Withdrawal
8. Craving
9. Drinking impairs functioning at work, school or home
10. Continued drinking despite alcohol-related social or interpersonal problems
11. Drinking in physically hazardous situations
Differences in Past Year Prevalence, Diagnosis and Treatment of Alcohol Use Disorders in Diverse Populations Residing in San Diego County

Compiled by the Center for Applied Research Solutions (CARS, 2010) for the California Dept. of Alcohol and Drug Programs (ADP)

<table>
<thead>
<tr>
<th>MALES vs FEMALES</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Binge Drinking</td>
<td>37%</td>
<td>25%</td>
</tr>
<tr>
<td>Alcohol or Drug (AOD) Treatment</td>
<td>65%</td>
<td>35%</td>
</tr>
<tr>
<td>Alcohol Related Car Accidents</td>
<td>73%</td>
<td>23%</td>
</tr>
<tr>
<td>Hospitalization Due to Alcohol-Related Causes</td>
<td>38%</td>
<td>32%</td>
</tr>
<tr>
<td>Race/Ethnicity</td>
<td>Binge Drinking</td>
<td>AOD Treatment</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>American Indian</td>
<td>37%</td>
<td>2%</td>
</tr>
<tr>
<td>Asian</td>
<td>13%</td>
<td>3%</td>
</tr>
<tr>
<td>Black</td>
<td>30%</td>
<td>12%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>32%</td>
<td>32%</td>
</tr>
<tr>
<td>White</td>
<td>34%</td>
<td>47%</td>
</tr>
<tr>
<td>Other</td>
<td>38%</td>
<td>5%</td>
</tr>
</tbody>
</table>
# Hospitalizations and Deaths Due to Alcohol in San Diego County in 2007

<table>
<thead>
<tr>
<th>Condition</th>
<th>Hospitalizations</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol Polyneuropathy</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Alcohol Cardiomyopathy</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Alcohol Poisoning</td>
<td>38</td>
<td>17</td>
</tr>
<tr>
<td>Alcoholic Gastritis</td>
<td>79</td>
<td>1</td>
</tr>
<tr>
<td>Alcohol Abuse</td>
<td>112</td>
<td>40</td>
</tr>
<tr>
<td>Alcohol Dependent Abuse</td>
<td>266</td>
<td></td>
</tr>
<tr>
<td>Alcoholic Liver Disease</td>
<td>659</td>
<td>253</td>
</tr>
<tr>
<td>Alcohol Psychosis</td>
<td>698</td>
<td>7</td>
</tr>
<tr>
<td>Alcohol Dependence Syndrome</td>
<td>1,578</td>
<td>29</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>3,448</strong></td>
<td><strong>353</strong></td>
</tr>
<tr>
<td><strong>Alcohol-Involved Motor Vehicle Injuries</strong></td>
<td><strong>2,068</strong></td>
<td><strong>116</strong></td>
</tr>
</tbody>
</table>
Alcohol Use Disorders Can Undermine Diagnosis and Treatment of Comorbid Medical Conditions

- Postpone seeking treatment
- Engage in risky behaviors
- Failure to follow medication regimens
- Contribute to conditions such as liver disease
- Weaken immune system
- Increase risk of side effects from some medications
- Can reduce efficacy of some medications
Alcohol Use Disorder is a large unmet medical need
• Accounts for 3.8% of all deaths and 4.6% of disability-adjusted life-years globally

• Costs exceed 1% of the gross national product of high and middle income countries

Existing treatments are grossly underutilized
• Approved pharmacological treatments are prescribed for < 9% of Americans with alcohol dependence

• Worldwide sales of approved treatments
  – Disulfiram (Antabuse): ?
  – Naltrexone (ReVia, Vivitrol): $41M
  – Acamprosate (Campral): $81M
Medication Targets in the Cycle of Alcoholism

- Acute Withdrawal
- Protracted Withdrawal
- Binge/Intoxication
Rational Drug Development for Alcohol Use Disorder

• Identify and preclinically validate targets relevant to treating persisting negative emotional states associated with the withdrawal/negative affect and preoccupation/anticipation (“craving”) stages of the addiction cycle

• Reliable, valid and correct human laboratory models for proof of concept (POC)

• New pharmacotherapies with larger effect sizes and good safety and tolerability profiles
Medications Development for Treatment of Alcoholism and Addiction

Koob GF, Lloyd GK, Mason BJ. *Nat Rev Drug Discovery* 2009; 8:500
Grant number R01 AA012602; 1999 – present

Screening Animal Studies – Multiple Models

Novel Analogs

New Use of Approved Drugs Investigational Drugs

Human Laboratory Studies – Multiple Dependent Variables

Phase II Clinical Trials
Rationale for Gabapentin as a Potential Treatment for Alcohol Dependence

FDA-approved for epilepsy and pain (Neurontin)
- Enhances GABAergic function via an action on voltage-gated calcium channels (Sills, 2006)
- Normalizes alcohol-related dysregulation in GABA-CRF interactions in the extended amygdala (Roberto et al., 2008)

Used off-label to treat symptoms associated with protracted withdrawal and risk of relapse
- Disturbances in mood and insomnia (Brower et al., 2008)

Safe and well-tolerated in acute withdrawal and in combination with alcohol (e.g., Myrick et al., 1998, 2007)
- Not appreciably metabolized in the liver
Laboratory Studies: Gabapentin Effects on Drinking and Craving

**Human Studies**

• Safe, but no efficacy for a single dose in an alcohol administration paradigm in normal subjects
  - Bisaga & Evans, 2006

• Safe, but no efficacy for 1-week dosing in an alcohol administration/consumption paradigm in alcoholics
  - Myrick et al., 2007

**Pre-Clinical**

• Dose-dependent reduction in ethanol self-administration in dependent rats

• No effect in non dependent rats
  - Roberto et al., 2008
POC Human Laboratory
Cue Reactivity Study:
Gabapentin in Alcohol Dependence

Week 0: Randomization
n= 33

Week 1: Laboratory Cue Session

Days 0-7
Gabapentin
1200mg

Days 0-7
Placebo
VAS Craving Scores: Alcohol Minus Water

* p < 0.05
** p < 0.1

[Bar chart showing VAS craving scores for Alcohol Minus Water with bars for Strength, Impulse, Control, and Relief. The chart includes Placebo and Gabapentin conditions.]
Effect of Gabapentin vs Placebo on Pittsburgh Sleep Quality Index\(^1\)

1 Higher values indicate greater disturbance; subscale range 0-2

\(***p < 0.001; **p < 0.05; *p < 0.06\)
Gabapentin Does Not Show Abuse Potential on the Addiction Research Center Inventory (ARCI)

The bar chart compares the mean ARCI scores for various drug groups: Placebo and Gabapentin. 

- Benzadrine: Placebo > Gabapentin
- Phenobarbital Clorpromazine Alcohol: Placebo > Gabapentin
- Morphine Benzadrine: Placebo > Gabapentin
- LSD: Placebo > Gabapentin
- Amphetamine: Placebo > Gabapentin
POC Cue Reactivity Human Laboratory Study

Gabapentin vs placebo was associated with
• decreased craving (p < .05)
• improved sleep (p < .05)
• good safety and tolerability
• no evidence of abuse potential

A randomized controlled trial (RCT) to evaluate the efficacy of gabapentin for relapse prevention in alcohol dependence is warranted.

Mason et al., 2008
Gabapentin Treatment for Alcohol Dependence
A Randomized Clinical Trial

Barbara J. Mason, MD; Susan Quello, BA, BS; Vivien Goodell, MPH; Farhad Sheikh, MD; Mark Kyle, MD; Adrian Begovic, MD

Importance. Approved medications for alcohol dependence are prescribed for less than 9% of US alcoholics.

Objective. To determine if gabapentin, a widely prescribed generic calcium-channel α2-δ-ligand, a neuronally modulating medication, increases rates of sustained abstinence and no heavy drinking and decreases alcohol-related insomnia, dysphoria, and craving, in a dose-dependent manner.

Design, Participants, and Setting. A 12-week, double-blind, placebo-controlled, randomized dose-ranging trial of 150 men and women older than 18 years with current alcohol dependence, conducted from 2004 through 2010 at a single-site, outpatient clinical research facility adjoining a general medical hospital.

Interventions. Oral gabapentin (doses of 0 [placebo], 900 mg, or 1800 mg/d) and concomitant manual-guided counseling.

Main Outcomes and Measures. Rates of complete abstinence and no heavy drinking (primary) and changes in mood, sleep, and craving (secondary) over the 12-week study.

Results. Gabapentin significantly improved the rates of abstinence and no heavy drinking. The abstinence rate in the placebo group was 4.1% (95% CI, 1.1%-13.7%) and 11.1% (95% CI, 5.2%-22.1%) in the 900-mg group, and 17.0% (95% CI, 8.9%-30.1%) in the 1800-mg group (P = .04 for linear dose effect; number needed to treat [NNT] = 8 for 900 mg). The no-heavy-drinking rate was 22.5% (95% CI, 13.6%-37.2%) in the placebo group, 29.6% (95% CI, 19.6%-42.8%) in the 900-mg group, and 44.7% (95% CI, 31.4%-58.8%) in the 1800-mg group (P = .02 for linear dose effect; NNT = 5 for 1800 mg). Similar linear dose effects were obtained with measures of mood (F3, 373 = 7.3; P < .001), sleep (F3, 373 = 13.6; P < .001), and craving (F3, 350 = 3.56; P = .03). There were no serious drug-related adverse events, and terminations owing to adverse events (9 of 150 participants), time in the study (mean [SD], 91 ± 38 weeks), and rate of study completion (85 of 150 participants) did not differ among groups.

Conclusions and Relevance. Gabapentin (particularly the 1800-mg dosage) was effective in treating alcohol dependence and relieved-related symptoms of insomnia, dysphoria, and craving, with a favorable safety profile. Increased implementation of pharmacological treatment of alcohol dependence in primary care may be a major benefit of gabapentin as a treatment option for alcohol dependence.

Trial Registration. clinicaltrials.gov Identifier: NCT00391715

Author Affiliations. The Scripps Research Institute, La Jolla, California (Mason, Quello, Goodell); Scripps Clinic and Scripps Clinic, La Jolla, California (Kyle, Begovic); corresponding author: Barbara J. Mason, MD, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037 (mason@scripps.edu).
Hypothesis

Gabapentin will have efficacy for the treatment of alcohol dependence by

• acting directly on drinking behavior
  – rates of abstinence and no heavy drinking
  – drinking quantity and frequency

• acting on symptoms of protracted withdrawal that may modulate drinking behavior, e.g., craving and disturbances in mood and sleep
Methods

Procedures

• Double-blind

• Random assignment

• Dose-ranging: 0, 900, 1800 mg/d gabapentin

• 12-week study duration and post treatment follow up at Weeks 13 and 24

• Weekly abstinence-oriented counseling (www.alcoholfree.info)
## Gabapentin Dose Titration Schedule:
Number of 300 mg Capsules Dispensed

<table>
<thead>
<tr>
<th></th>
<th>Morning</th>
<th>Afternoon</th>
<th>Evening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>○○</td>
<td>○○</td>
<td>●○</td>
</tr>
<tr>
<td>Day 2</td>
<td>●○</td>
<td>○○</td>
<td>●○</td>
</tr>
<tr>
<td>Day 3</td>
<td>●○</td>
<td>●○</td>
<td>●○</td>
</tr>
<tr>
<td>Day 4</td>
<td>●○</td>
<td>●○</td>
<td>●●</td>
</tr>
<tr>
<td>Day 5</td>
<td>●●</td>
<td>●○</td>
<td>●●</td>
</tr>
<tr>
<td>Day 6 - 78</td>
<td>●●</td>
<td>●●</td>
<td>●●</td>
</tr>
<tr>
<td>Day 79 - 84</td>
<td></td>
<td></td>
<td>Reverse Titration</td>
</tr>
</tbody>
</table>

○○ ○ ○ ●○ ○ ○ ●○ ○ ○ ●○ ●○ ●○ ●○ ●● ○ ○ ●● ●○ ●● ●● ●●

Day 1: Start with 2 capsules in the morning, 2 capsules in the afternoon, and 1 capsule in the evening.
Day 2: Increase by 1 capsule in the morning and 1 capsule in the evening.
Day 3: Increase by 1 capsule in the morning.
Day 4: Increase by 1 capsule in the morning.
Day 5: Increase by 1 capsule in the morning.
Day 6-78: Continue the last dose.
Day 79-84: Reverse titration, start reducing the dosage by 1 capsule in the morning and 1 capsule in the evening until the original dose is reached.

○○ ○ ○ ●○ ○ ○ ●○ ○ ○ ●○ ●○ ●○ ●○ ●● ○ ○ ●● ●○ ●● ●● ●●

○○ ○ ○ ●○ ○ ○ ●○ ○ ○ ●○ ●○ ●○ ●○ ●● ○ ○ ●● ●○ ●● ●● ●●

Day 1: Start with 2 capsules in the morning, 2 capsules in the afternoon, and 1 capsule in the evening.
Day 2: Increase by 1 capsule in the morning and 1 capsule in the evening.
Day 3: Increase by 1 capsule in the morning.
Day 4: Increase by 1 capsule in the morning.
Day 5: Increase by 1 capsule in the morning.
Day 6-78: Continue the last dose.
Day 79-84: Reverse titration, start reducing the dosage by 1 capsule in the morning and 1 capsule in the evening until the original dose is reached.

○○ ○ ○ ●○ ○ ○ ●○ ○ ○ ●○ ●○ ●○ ●○ ●● ○ ○ ●● ●○ ●● ●● ●●
Methods

Dependent Measures

• Timeline Follow Back Interview (Sobell & Sobell, 1992)
• Alcohol Craving Questionnaire (Singleton et al., 1994)
• Pittsburgh Sleep Quality Index (Buysse et al., 1989)
• Beck Depression Inventory-II (Beck et al., 1996)
Methods

Admission Criteria

• Males or females over 18 years of age

• DSM IV criteria for current alcohol dependence

• Abstinent 3 to 30 days

• No major medical or psychiatric conditions, including depressive, anxiety or dependence disorders other than alcohol or nicotine dependence

• No treatment with other psychoactive medications
Disposition of Patients

Patients Screened  n= 185

Randomization  
n= 150

Excluded  n= 35  
19 not eligible  
16 declined

Weeks 0-12  
Aisstance-Oriented Counseling

Placebo  
n= 49

59.4 Days on Study  
30 Completed

900mg Gabapentin  
n = 54

63.0 Days on Study  
26 Completed

1800mg Gabapentin  
n = 47

68.2 Days on Study  
29 Completed

Weeks 13 and 24 Post Treatment Follow-up
# Baseline Characteristics (n = 150)

## Demographics
- **Age, years**: 44.5
- **Male**: 55%
- **White, non-Hispanic**: 81%

## Drinking Characteristics
- **Years heavy drinking**: 14.4
- **Drinks per week**: 42.8
- **Drinking days per week**: 5.3
- **Consecutive days abstinent before study**: 3.0

---

1. No between group differences
2. 5+ drinks per day (males), 4+ drinks per day (females)
3. During the 90 days before screening
Rates of Complete Abstinence and No Heavy Drinking on Study

A 40
Linear dose effect
p=0.041

B 80
Linear dose effect
p=0.02

% of Subjects

Complete Abstinence
NNT = 8 for 1800 mg

No Heavy Drinking
NNT = 5 for 1800 mg
Gabapentin effects on number of drinks per week and number of heavy drinking days per week during the 12-week study in the intention-to-treat population (N=150).
Cumulative Number of Drinks per Week Post Treatment Follow up

- Placebo
- 900mg
- 1800mg

$p<0.05$
Alcohol Craving Questionnaire

Linear dose effect $p=0.019$
Beck Depression Inventory

Linear dose effect p<0.001
Pittsburgh Sleep Quality Index: Total Scores

Linear dose effect $p<0.020$
Pittsburgh Sleep Quality Index

A. Sleep Quality

B. Daytime Dysfunction

Linear dose effect p<0.001
## Medication Tolerability and Compliance

<table>
<thead>
<tr>
<th>Adverse Experience</th>
<th>Placebo N=49</th>
<th>900mg N=54</th>
<th>1800mg N=47</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>24%</td>
<td>24%</td>
<td>19%</td>
</tr>
<tr>
<td>Headache</td>
<td>16%</td>
<td>13%</td>
<td>13%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>22%</td>
<td>19%</td>
<td>13%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>12%</td>
<td>3.7%</td>
<td>11%</td>
</tr>
<tr>
<td>Compliance</td>
<td>96.8%</td>
<td>95.6%</td>
<td>96.2%</td>
</tr>
</tbody>
</table>
Summary

• Gabapentin dose dependently, significantly improved
  - rates of complete abstinence and no heavy drinking
  - drinking quantity and frequency
  - GGT
  - alcohol craving
  - sleep disturbance
  - negative affective symptoms

• Gabapentin was well-tolerated with no serious or unexpected drug-related adverse events or evidence of abuse potential
Clinical Implications

• Gabapentin is a cost-effective treatment for alcohol dependence.

• Dose response effects on drinking were found throughout 12 weeks of double-blind treatment and 24 weeks of post treatment follow up, suggesting a return to homeostasis in brain stress systems with no evidence of tolerance or rebound symptoms with drug off titration.

• Although non compliance may be an issue with disulfiram and naltrexone, patients complied with a treatment associated with reduced drinking and improved mood, sleep and craving.

• Positive outcomes for gabapentin lend support to the role of neuromodulating drugs that target the dysregulation in brain stress systems associated with protracted abstinence for the treatment of alcohol dependence.
Challenges
No industry support for FDA approval of a new use for a generic drug that has shown promise for treating CNS disorders, e.g., alcohol dependence, that have few effective treatment options.

Advantages
Alcohol dependence is found – and gabapentin is widely used – across medical specialties. Reported benefits of gabapentin for alcohol dependence may result in a broader interest in alcoholism treatment across diverse medical settings.
Acknowledgements

The Scripps Research Institute
- Susan Quello, BA, BS
- Vivian Goodell, MPH
- Jamie Kissee, MA
- Melissa St. John

Scripps Clinical and Scripps Green Hospital
- Farhad Shadan, MD, PhD
- Mark Kyle, MD
- Adnan Begovic, MD

The National Institute on Alcohol Abuse and Alcoholism
The National Institute on Drug Abuse